MELANIE ISBELL: Open Payments
NPI 1720054240 · GLASGOW, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$636 in 29 payments from 11 companies in 2025. Trend: 2023 $1,654 · 2024 $750 · 2025 $636
Food & beverage: $550Education: $87
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $151 |
| PFIZER INC. | 4 | $91 |
| E.R. Squibb & Sons, L.L.C. | 4 | $90 |
| Novartis Pharmaceuticals Corporation | 4 | $86 |
| ABBVIE INC. | 5 | $85 |
| Stemline Therapeutics Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $26 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Celgene Corporation | 1 | $20 |
| PUMA BIOTECHNOLOGY, INC. | 1 | $18 |
Products named: OPDUALAG, VENCLEXTA, SCEMBLIX, XTANDI, IBRANCE, LYNPARZA, ENHERTU, Orserdu.
Industry payments across KY — which companies pay providers there.
